The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles

BACKGROUND: Bevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly potent in cell culture and efficacious in HIV-1 infected patients. In contrast to inhibitors that target the active site of the viral protease, bevirimat specifically inhibits a single cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Albert T, Feasley, Christa L, Jackson, Ken W, Nitz, Theodore J, Salzwedel, Karl, Air, Gillian M, Sakalian, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267693/
https://www.ncbi.nlm.nih.gov/pubmed/22151792
http://dx.doi.org/10.1186/1742-4690-8-101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267693/
https://www.ncbi.nlm.nih.gov/pubmed/22151792
http://dx.doi.org/10.1186/1742-4690-8-101

Ejemplares similares